aTYR PHARMA INC Operating Lease Liability
aTYR PHARMA INC (ATYR) had Operating Lease Liability of $10.74 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-07
- 2026-06-30: Operating Lease, Liability $10.74M.
- 2026-03-31: Operating Lease, Liability $10.95M.
- 2025-12-31: Operating Lease, Liability $11.14M.
- 2025-09-30: Operating Lease, Liability $11.33M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $10.74M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $10.95M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $11.14M 10-K · filed 2026-03-05 |
| 2025-09-30 | $11.33M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $11.51M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $11.69M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $11.86M 10-K · filed 2025-03-13 |
| 2024-09-30 | $12.01M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $12.17M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $12.32M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $13.47M 10-K · filed 2024-03-14 |
| 2023-09-30 | $13.73M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $14.07M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $12.95M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $13.02M 10-K · filed 2023-03-14 |
| 2022-09-30 | $12.45M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $906.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.15M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.38M 10-K · filed 2022-03-15 |
| 2021-09-30 | $1.61M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.82M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $2.04M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $2.24M 10-K · filed 2021-03-24 |
| 2020-09-30 | $2.44M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $2.63M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $2.81M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $2.99M 10-K · filed 2020-03-26 |
| 2019-09-30 | $3.17M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $3.34M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $3.50M 10-Q · filed 2019-05-14 |
| 2019-01-01 | $3.50M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |